Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Dignitana Q1’22: Initial comments

2022-05-19

09:03

MH

Mats Hyttinge

Redeye’s first comments on the Q1 report released earlier this morning that showed continued good growth and an impressive increase in the Average Daily Treatment Revenue. The costs were higher than expected but not materially. A clear improvement in the operating cash flow is a definite positive.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers